| Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy V Kumar, N Chaudhary, M Garg, CS Floudas, P Soni, AB Chandra Frontiers in pharmacology 8, 49, 2017 | 637 | 2017 |
| Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer C Xie, AG Duffy, D Mabry‐Hrones, B Wood, E Levy, V Krishnasamy, ... Hepatology 69 (5), 2048-2060, 2019 | 93 | 2019 |
| The contemporary management of cancers of the sinonasal tract in adults R Thawani, MS Kim, A Arastu, Z Feng, MT West, NF Taflin, KZ Thein, R Li, ... CA: a cancer journal for clinicians 73 (1), 72-112, 2023 | 80 | 2023 |
| Matching patients to clinical trials with large language models Q Jin, Z Wang, CS Floudas, F Chen, C Gong, D Bracken-Clarke, E Xue, ... Nature Communications 15 (1), 9074, 2024 | 71 | 2024 |
| Applications of large language models in cancer care: current evidence and future perspectives GM Iannantuono, D Bracken-Clarke, CS Floudas, M Roselli, JL Gulley, ... Frontiers in Oncology 13, 1268915, 2023 | 54 | 2023 |
| Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy V Kumar, N Chaudhary, M Garg, CS Floudas, P Soni, AB Chandra Frontiers in pharmacology 8, 311, 2017 | 50 | 2017 |
| Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) M Bilusic, S McMahon, RA Madan, F Karzai, YT Tsai, RN Donahue, ... Journal for immunotherapy of cancer 9 (3), 2021 | 43 | 2021 |
| A pilot study of the PD-1 targeting agent AMP-224 used with low-dose cyclophosphamide and stereotactic body radiation therapy in patients with metastatic colorectal cancer CS Floudas, G Brar, D Mabry-Hrones, AG Duffy, B Wood, E Levy, ... Clinical colorectal cancer 18 (4), e349-e360, 2019 | 40 | 2019 |
| Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC). CS Floudas, C Xie, G Brar, MP Morelli, S Fioravanti, M Walker, ... Journal of Clinical Oncology 37 (4_suppl), 336-336, 2019 | 40 | 2019 |
| Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer PJ DeMaria, K Lee-Wisdom, RN Donahue, RA Madan, F Karzai, ... Journal for immunotherapy of cancer 9 (9), 2021 | 30 | 2021 |
| Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival CS Floudas, AB Chandra, Y Xu Melanoma research 26 (3), 312-315, 2016 | 26 | 2016 |
| Identifying genetic interactions associated with late-onset Alzheimer’s disease CS Floudas, N Um, MI Kamboh, MM Barmada, S Visweswaran BioData mining 7, 1-19, 2014 | 26 | 2014 |
| Immunotherapy: current status and future perspectives CS Floudas, G Brar, TF Greten Digestive Diseases and Sciences 64, 1030-1040, 2019 | 25 | 2019 |
| Kikuchi’s lymphadenopathy: a relatively rare but important cause of lymphadenopathy in Greece, potentially associated with the antiphospholipid syndrome TP Vassilakopoulos, GA Pangalis, MP Siakantaris, G Levidou, ... Rheumatology international 30, 925-932, 2010 | 23 | 2010 |
| Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials GM Iannantuono, E Chandran, CS Floudas, H Choo-Wosoba, G Butera, ... Cancer Treatment Reviews, 102623, 2023 | 21 | 2023 |
| Loss of vision associated with angioid streaks in β-thalassemia intermedia A Aessopos, CS Floudas, M Kati, M Tsironi, X Giakoumi, C Livir-Rallatos, ... International journal of hematology 87, 35-38, 2008 | 21 | 2008 |
| Rheumatoid arthritis in thalassemia intermedia: coincidence or association? X Giakoumi, M Tsironi, C Floudas, E Polymeropoylos, E Papalambros, ... The Israel Medical Association Journal: IMAJ 7 (10), 667-669, 2005 | 21 | 2005 |
| Comparison of large language models in answering Immuno-oncology questions: a cross-sectional study GM Iannantuono, D Bracken-Clarke, F Karzai, H Choo-Wosoba, JL Gulley, ... The Oncologist 29 (5), 407-414, 2024 | 20 | 2024 |
| The genomics and epigenetics of olfactory neuroblastoma: A systematic review RP Kaur, E Izumchenko, DM Blakaj, N Mladkova, M Lechner, ... Laryngoscope investigative otolaryngology 6 (4), 721-728, 2021 | 19 | 2021 |
| Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies J Strauss, CS Floudas, HA Sater, M Manu, E Lamping, DC Francis, ... J. Clin. Oncol 39 (2501), 10.1200, 2021 | 19 | 2021 |
James L. GulleyNational Cancer InstituteVerified email at mail.nih.gov
